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Human immunodeficiency virus (HIV)–infected men who
have sex with men (MSM) were enrolled in an anorectal
Chlamydia trachomatis screening study. Anorectal Chlamy-
dia DNA was detected in 16 (10.9%) of 147 men, mainly
among asymptomatic patients and patients having120 sexual
partners. These results support routine anorectal Chlamydia
screening in HIV-infected MSM who report unprotected anal
intercourse.
In several Western countries, including Switzerland, an increas-
ing proportion of new human immunodeficiency virus (HIV)
infection is occurring in men who have sex with men (MSM).
Concomitantly, several European countries have recorded a re-
cent, substantial increase in the number of reported sexual-
ly transmitted diseases (STDs), particularly among MSM [1].
STDs, including nonulcerative, frequently asymptomatic infec-
tions such as Chlamydia trachomatis infection, are associated
with a several-fold increased likelihood of acquiring HIV in-
fection [2, 3]. Anorectal chlamydial infection might thus be a
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contributor to the uncontrolled HIV epidemic among MSM.
The aim of this study was to determine the prevalence and
clinical characteristics of anorectal chlamydial infection in HIV-
infected MSM who were followed up in the Swiss HIV Cohort
Study (SHCS) [4] and to evaluate the feasibility of anorectal
STD screening in routine HIV care.
Methods. Participants were enrolled in the SHCS, which
involves a standardized follow-up visit every 6 months that
includes questions about sexual activity and condom use [5].
From 1 April 2007 through 31 March 2008, consecutive MSM
participants who reported1 episode of unprotected receptive
anal intercourse in the previous 2 years and/or symptoms of
proctitis (rectal pain and/or discharge, cramps, bloody stools,
or new onset and/or unusual constipation) were invited to be
tested for anorectal chlamydial infection. All participants gave
written, informed consent, and the study was approved by the
ethics committees of participating SHCS centers.
A standardized questionnaire was used to record the follow-
ing: (1) sexual behavior (including use of sex toys, fisting, oro-
anal contact, and trading sex for money), (2) number of sex
partners within the previous 2 years, (3) knowledge of partner’s
HIV serostatus, (4) history of STD, and (5) anorectal, urogen-
ital, or systemic symptoms at the time of the visit. Data on
demographic characteristics, CD4 cell count, HIV viral load,
current antiretroviral therapy, syphilis, hepatitis B virus infec-
tion, and hepatitis C virus infection were retrieved from the
SHCS database. Study physicians were provided with kits that
contained the questionnaire, a sterile dry cotton-tipped swab
(Eurotubo; Deltalab), a sterile tube containing 500 ml of DNA-
free water, and detailed instructions. Specimens were obtained
by the treating physician by passing the swab 3–4 cm into the
anal canal and by rubbing the swab against the anal wall with
a rotating motion for 30 seconds. Anorectal cells were exudated
from the swab by pressing the swab inside the DNA-free water
tube.
All specimens were processed at the Institute of Microbiology
in Lausanne. Samples were screened for the presence of C.
trachomatis DNA by means of a TaqMan real-time polymerase
chain reaction (PCR) assay that targeted the cryptic plasmid
of C. trachomatis, as described elsewhere [6]. This validated
assay also detects strains that contain a recently identified 350
bp deletion in the cryptic plasmid [7], because the 71 bp DNA
fragment amplified is located 93 bp downstream from the de-
letion. Positive samples were genotyped by partial amplification
and sequencing of the C. trachomatis ompA gene fragments, as
described elsewhere [8]. Obtained sequences were compared
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Table 1. Risk Factors Associated with Anorectal Chlamydia trachomatis Infection among 147 Male Homosexual Participants in the
Swiss HIV Cohort Study
Variable
With anorectal
C. trachomatis
infection
(n p 16)
Without anorectal
C. trachomatis
infection
(n p 131)
OR (95% CI),
by univariate analysis P
Medical history and clinical characteristics
Age, median years (IQR) 39.5 (32–47) 42 (27–65) 0.75 (0.39–1.41)a .39
Median CD4 cell count 529 cells/mL 459 cells/mL 0.35 (0.03–3.59)b .37b
HIV-1 RNA !40 copies/mL 11 (69) 77 (59) 0.36 (0.21–1.97) .44
Current combination antiretroviral therapy 13 (81) 93 (71) 1.77 (0.47–6.56) .55
Drug usec 5 (31) 38 (29) 1.11 (0.36–3.41) .85
Alcohol misused 5 (31) 51 (39) 0.71 (0.23–2.17) .59
Hepatitis C seropositivity 2 (13) 10 (8) 1.83 (0.36–9.27) .36
Chronic hepatitis B infection 0 (0) 9 (7) .59
Concurrent proctitis symptoms 3 (19) 25 (19) 0.97 (0.25–3.69) 1.99
Concurrent urogenital symptoms 1 (6) 12 (9) 0.66 (0.08–5.45) 1.99
History of STDs 11 (69) 88 (67) 1.07 (0.35–3.28) .89
Chlamydial infection 4 (25) 31 (24) 1.07 (0.32–3.57) 1.99
Gonorrhea 5 (31) 58 (44) 0.57 (0.18–1.73) .32
Syphilise 9 (56) 55 (42) 1.77 (0.62–5.06) .28
Sexual behavior and practices within previous 2 years
Median no. of partners (IQR) 22 (10–100) 6 (2–13) 1.01 (1–1.02)f .002
120 sex partners 8 (50) 17 (13) 5.64 (1.86–17.09) .001
Intercourse with HIV-infected partner(s) or declines to answer 14 (88) 92 (70) 2.96 (0.64–13.67) .23
Consistent condom use with occasional partnerg 8 (50) 51 (39) 0.63 (0.22–1.80) .39
Any anal insertive sex 11 (69) 79 (60) 1.44 (0.47–4.40) .51
Any oral insertive sex 13 (81) 84 (64) 2.42 (0.65–8.94) .26
Any vaginal insertive sex 1 (6) 4 (3) 2.11 (0.22–20.19) .44
Any oral receptive sex 14 (88) 102 (78) 1.99 (0.42–9.26) .52
Being fisted 1 (6) 15 (11) 0.51 (0.06–4.18) 1.99
Use of anal toys 7 (44) 33 (25) 2.30 (0.79–6.69) .12
Oro-anal contact 9 (56) 71 (54) 1.08 (0.38–3.09) .88
Ever exchanged money for sex 1 (6) 14 (11) 0.55 (0.06–4.54) 1.99
NOTE. Values shown are no. (%) of patients, unless otherwise indicated. CI, confidence interval; HIV, human immunodeficiency virus; IQR, interquartile
range; OR, odds ratio; STD, sexually transmitted disease.
a Per 10-year increase in age.
b
!200 cells/mL vs 200 cells/mL.
c Injection or noninjection drug use within the previous 6 months.
d Daily consumption of 30 g alcohol.
e Positive serum Treponema pallidum hemagglutination assay.
f Per 1 sex partner increase, within the previous 2 years.
g Always used condoms with occasional partners during the previous 6 months.
with Chlamydia GenBank sequences for serovar identification.
In addition, the presence of Neisseria gonorrhoeae DNA was
investigated in all specimens by means of a specific homemade
TaqMan PCR assay that targeted the 5′ region of the porA gene
with the following primers and probes: NgF 5′ CGAAGTCAA
AGCTGGTGTGG, NgR 5′ TAACTGTATTGCCCGTTTGAC
CTT, and NgS 5′ VIC CAGTTGACCGAGCCAC– MGB at con-
centrations of 200 nmol (primers) and 100 nmol (probe). This
homemade PCR assay exhibits an excellent specificity, as shown
by the fact that no amplification was detected when testing 10
ng of DNA extracted from various bacterial species: Neisseria
lactamica, Neisseria meningitidis, Neisseria subflava, Neisseria wea-
veri, Enterococcus faecalis, Escherichia coli, Pseudomonas aerugi-
nosa, Staphylococcus species, and Streptococcus pyogenes.
Demographic data and risk factors were compared between
patients with and patients without C. trachomatis infection by
the Pearson x2 test (or the Fisher exact test when indicated)
for categorical variables. For continuous variables, medians
were compared by the Wilcoxon-Mann-Whitney test. Multi-
variate logistic regression was performed to identify factors in-
dependently associated with C. trachomatis infection. All anal-
yses were performed using Stata, version 10 (StataCorp).
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Results. Very few patients declined to be screened, and the
anorectal swabbing procedure was found to be acceptable and
minimally discomforting by all study participants. Of 157 spec-
imens received in the laboratory, 10 were rejected because of
either protocol violation ( ), missing questionnaire (np 6 np
), or noninterpretable result due to presence of PCR inhibi-2
tors ( ). The final analysis thus included 147 anal speci-np 2
mens obtained from 147 participants, with the following char-
acteristics: white race, 93%; median age, 42 years (range, 22–
72 years); at least high-school education, 93%; median CD4
cell count, 459 cells/mL (interquartile range, 332–676 cells/mL);
receipt of antiretroviral therapy, 72%; HIV-1 RNA !40 copies/
mL, 60%; illicit or recreational drug use, 29%; and history of
STD, 67% (Table 1).
Anorectal C. trachomatis DNA was detected in 16 (10.9%)
of the 147 specimens (95% confidence interval [CI], 6.2%–
17.6%) and N. gonorrhoeae DNA in 4 (2.7%; 95% CI, 0.9%–
7.3%). No participant had concomitant C. trachomatis and N.
gonorrhoeae infection. There was 1 lymphogranuloma vene-
reum (LGV) serovar. The non-LGV serovars included G (np
), J ( ), E ( ), and D ( ). Serovars could not be5 np 4 np 2 np 1
determined in 3 samples because of very low bacterial loads
(threshold cycles between 37 and 40.4). Current proctitis symp-
toms were reported by 28 participants; infection with C. tra-
chomatis was found in 3 participants, and N. gonorrhoeae was
found in 1 of these. The participant with anorectal LGV had a
7-day history of rectal discharge, cramps, and bloody stools. He
had a history of C. trachomatis proctitis and syphilis and report-
ed 160 partners during the previous 2 years.
Table 1 shows the characteristics of patients with ( )np 16
and those without ( ) anorectal chlamydial infection.np 131
Proctitis symptoms were not associated with chlamydial infec-
tion. Having 120 sex partners within the previous 2 years was
reported by 8 (50%) of the 16 participants with chlamydial in-
fection, compared with 17 (13%) of the 131 participants without
chlamydial infection. In a model adjusted for age (per 10 years),
insertive anal intercourse, and inconsistent condom use, the odds
ratio of anorectal C. trachomatis infection was 5.52 (95% CI,
1.78–17.11) for participants with 120 partners within the pre-
vious 2 years. There was a trend ( ) toward anal toy usePp .12
being associated with anorectal chlamydial infection.
Discussion. The main finding of our study is a high prev-
alence of anorectal C. trachomatis infection among HIV-in-
fected MSM in Switzerland who report unprotected sexual ac-
tivity, most of whom presented for routine HIV care. The high
prevalence together with a strong association with multiple sex
partners and their presumed potential for facilitating HIV
transmission suggest a possible role for anorectal chlamydial
infection in sustaining the ongoing HIV epidemic among MSM
in Switzerland. Consistent with prior reports [9], most ano-
rectal chlamydial infections were asymptomatic, indicating the
need for increased awareness of these infections among HIV-
infected MSM. Our findings underscore a potential role for
expanded rectal chlamydial screening in the reduction of the
number of new HIV infections among MSM, a group for whom
increased HIV prevention efforts are particularly needed. Early
detection and treatment of curable STDs was already recom-
mended in a 1998 report by the United States Centers for
Disease Control and Prevention (CDC) that also highlighted
the importance of asymptomatic infection [3]. Moreover, the
CDC recommends at least annual screening for rectal STDs in
MSM who report receptive anal intercourse [10].
Our findings are consistent with the high rectal chlamydial
infection rate among MSM with newly diagnosed HIV infection
in San Francisco [11] and may be related to increased sexual
risk-taking behavior among MSM in the era of antiretroviral
therapy. In contrast, only one participant had LGV, consistent
with the low rectal LGV rate in patients at STD clinics in the
United Kingdom [12]. This argues against anorectal LGV be-
ing a major driver of the recent doubling of the number of new
HIV infections among MSM in Switzerland.
In our data set, the only risk factor for anorectal chlamydial
infection was the number of sex partners in the previous 2
years. Detection of additional associations with specific sexual
practices presumably was limited by the fact that participants
were selected for unprotected anal intercourse, a marker for
high-risk sexual activity.
In contrast to previous studies that investigated anorectal
chlamydial infection among patients at STD clinics [12, 13],
most participants in our study presented for routine HIV care
to SHCS-affiliated physicians and were consecutively enrolled
on the basis of a single, simple screening question (unprotected
anal intercourse in the previous 2 years). We therefore believe
that our data represent the current epidemiology of anorectal
chlamydial infection in a population representative of sexually
active HIV-infected MSM in Switzerland. In conclusion, regular
anorectal chlamydial screening should be strongly considered
in all HIV-infected MSM who report unprotected anal inter-
course, irrespective of symptoms. Additional studies should ad-
dress the incidence of other anorectal STDs in high-risk HIV-
infected MSM, the appropriate frequency of screening, and the
indication to screen for other STDs in this setting.
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